Chemomab appoints Jill M. Quigley to board of directors

Chemomab Therapeutics Ltd.

Jill M. Quigley appointed to Chemomab board and audit committee, effective June 16, 2022.
Quigley brings 20+ years biotech experience, including COO of Passage Bio and CEO of Nutrinia.
Board expands to seven directors; audit committee now includes Quigley as financial expert.
Quigley also serves on Terns Pharmaceuticals board (TERN) and chairs its audit committee.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jill M. Quigley

Director

CMMB · Chemomab Therapeutics Ltd.

Effective: 2022-06-16
Filed: June 21, 2022, 7:59 PM ET

appointed Jill M. Quigley to the Board and the audit committee of the Board (the “Audit Committee”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jill M. Quigley was appointed as Director at Chemomab Therapeutics Ltd..

Action: appointed
Role: Director

Exact text from the filing

appointed Jill M. Quigley to the Board and the audit committee of the Board (the “Audit Committee”), effective immediately.

View on SEC.gov

Chemomab Therapeutics Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-22-002410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.